12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

Stem Cell Therapeutics, University Health Network (UHN) deal

UHN granted the company an option to license exclusive, worldwide rights to tigecycline for cancer indications. The glycylcycline antibiotic is in a Phase I trial in patients with...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >